Translating basic science into clinical practice

Programme

Download Click here to download a PDF version of the conference programme (2MB).

  Conference Lecture Theatre   Bridge –Deck (Lecture Theatre II)   Quarter Deck (Lecture Theatre III)   Exhibition Hall
Wednesday 9th July
  Session/Timings Title Speaker Affiliation
  16.15-16.30 Opening Ceremony Sir James Drummond Bone
Lord Falconer of Thoroton		 University of Liverpool, UK
House of Lords, UK
  1: 16.30-17.30 Chairperson Dr Jim Mulshine
  Key Note: Global Lung Cancer: International issues, successes & future opportunities Dr Peter Boyle IARC, Lyon, France
  17.30-18.30 Welcome reception – Galleria
  19.30 Speakers Dinner – Town Hall
Thursday 10th July
  Session/Timings Title Speaker Affiliation
  2A: 07.30-08.30 Education Session (Meet the Professor)    
Lung Cancer Radiotherapy - trial recruitment issues Dr Matthew Hatton Weston Park Hospital, Sheffield, UK
  2B: 07.30-08.30 Abbott Sponsored Session    
Clinical utility of tumor markers in the aid of diagnosis and histological diagnosis of lung cancer Dr Rafael Molina IDIBAPS Hospital Clinic, Barcelona, Spain
  3: 08.30-09.00 Chairperson Prof John K Field
Key Note: Lung Cancer: The NCRI Strategic Plan Prof Mike Richards St Thomas Hospital, London, UK
  4: 09.00-10.45 Molecular Profiling of Lung Cancer
Chairpersons		   Prof Adi Gazdar
Dr Rob van Klaveren
09.00-09.20 Epigenetic mechanisms in epithelial cancers Dr Tim Crook Imperial College, London, UK
09.20-09.40 Circulating DNA as diagnostic marker for early detection of lung cancer Professor Gabriella Sozzi Fondazione IRCCS Istituto Nazionale Tumori, Italy
09.40-10.00 DNA methylation surrogate biomarkers for diagnosis of NSCLC Dr Triantafillos Liloglou University of Liverpool,  UK
10.00-10.20 SHOX2, EN2 and EVX2, promising new lung cancer biomarkers Dr Volker Liebenberg Epigenomics,  Berlin, Germany
10.20-10.45 Panel Discussion
  10.45-11.30 Tea, Coffee & Exhibition Viewing
  5: 11.30-13.00 Eli Lilly Sponsored Session    
  Clinical management decisions in NSCLC, Vorsprung durch Technik Prof Nick Thatcher Christie Hospital, Manchester, UK
  Looking at the possibilities of tomorrow Dr Michael Lahn Bad Homburg, Germany
  13.00-14.30 Lunch, Poster & Exhibition Viewing
  6: 14.30-16.00 Liverpool City of Culture Symposium, EU-US Spiral CT Collaboration
Chairpersons		   Dr Bob Smith
Dr Jim Mulshine
14.30-14.50 International Early Lung Cancer Action Program Prof Claudia Henschke Weill-Cornell Medical Center , New York, USA
14.50-15.10 NELSON- CT screening trial Dr Rob van Klaveren University Hospital, Rotterdam, Netherlands
15.10-15.30 Lung cancer screening with CT Prof Denise Aberle David Geffen School of Medicine, UCLA, USA
15.30-15.50 Current status of CT screening Dr Jim Mulshine Rush University & Medical Centre, Chicago, USA
15.50-16.00 Panel Discussion    
  7A: 16.30-18.30 Diagnostic/Prognostic Markers
Chairpersons		   Prof Adi Gazdar
Prof Christian Brambilla
16.30-16.45 Trial designs to assess biomarkers in clinical practice Dr Lucinda Billingham University of Birmingham, UK
16.45-17.00 VEGF-A loop in stage 1 NSCLC cells predicts a good outcome Dr Jackeline Agorreta University of Navarra, Spain
17.00-17.15 FHIT gene inactivation in lung cancer patients Dr Carla Verri Fondazione IRCCS Istituto Nazionale Tumori, Italy
17.15-17.30 Splice isoforms of VEGF-A and its receptors in NSCLC Dr Marta Larrayoz University of Navarra, Spain
17.30-17.45 Isolation of tumour initiating cells from lung cancer Dr Giuseppe Viglietto Universitario Germaneto, Italy
17.45-18.00 Use of plasma and blood cell DNA concentration and LDH level as prognostic factor of NSCLC Dr Minglin Ho Changhua Christian Hospital, Taiwan
18.00-18.15 Autofluorescence bronchoscopy with spectral analysis Dr Paul Dhillon University Hospital Coventry, UK
18.15-18.30 Quantitative sputum cytology to detect lung cancer Dr David Snead University Hospital Coventry, UK
  7B: 16.30-18.30 Imaging & Radiotherapy
Chairpersons		   Dr Matthew Hatton
Dr Denise Aberle
16.30-16.45 Stereotactic body radiation therapy (SBRT) for lung cancer Dr Max Dahele Radiation Medicine Program, Canada
16.45-17.00 A proposal for the evaluation of stereotactic radiotherapy in early stage NSCLC Dr Corinne Faivre-Finn Christie Hospital, Manchester, UK
17.00-17.15 Radiotherapy in extensive-disease SCLC Dr Neil Bayman Christie Hospital, Manchester, UK
17.15-17.30 Prospective audit of information, psychosocial needs and symptoms using the LCSS, of lung cancer patients attending for palliative radiotherapy in a single institution Dr Nazia Mohammed Beatson West of Scotland Cancer Centre, Glasgow, UK
17.30-17.45 Towards a consistent approach for the prediction of radiation-induced lung toxicity Dr Christopher Boylan Christie Hospital , Manchester, UK
17.45-18.00 Evaluating target localisation and normal tissue irradiation using 4DCT Dr Rebecca Muirhead Beatson West of Scotland Cancer Centre, Glasgow, UK
18.00-18.15 Quality of life after radiotherapy and steroids in patients with inoperable brain metastases from NSCLC: The QUARTZ trial Dr Paula Mulvenna Newcastle General Hospital, UK
18.15-18.30 The impact of PET/CT on radiotherapy planning in lung tumours Dr Jamal Khader King Hussein Cancer Centre, Amman, Jordan
  7C: 16.30-18.30 Lung Cancer Management Recommendations
Chairpersons		   Dr Richard Stephens
Dr Mick Peake
16.30-16.45 The prognosis of completely re-sected p-stage 1A NSCLC - implications for adjuvant therapy Dr Masahiko Harada Komagome Hospital, Tokyo, Japan
16.45-17.00 The Multidisciplinary Team meeting in lung cancer Dr Craig Martin Norfolk and Norwich University Hospital, UK
17.00-17.15 Review of CHART for NSCLC in the West of Scotland Dr Brian Clark Beatson West of Scotland Cancer Centre, Glasgow, UK
17.15-17.30 Longer term quality of life following surgery for NSCLC Dr Penelope Hopwood Christie Hospital ,
Manchester, UK
17.30-17.45 The Northern Cancer Network Experience – Docetaxel in NSCLC Dr Louise Li Newcastle General Hospital, UK
17.45-18.00 Social and travel factors and treatment of lung cancer Dr S Michael Crawford Airedale General Hospital, Keighley, UK
18.00-18.15 Best supportive care in lung cancer trials : clinical and cost comparisons Dr Angela Boland University of Liverpool, UK
18.15-18.30 Panel Discussion
    UKLCC Sponsored Session    
  8: 18.30-20.30 Is your MDT fit for purpose? Dr Mick Peake Dame Gill Oliver Glenfield Hospital, Leicester, UK
Chair, UKLCC
Friday 11th July
  Session/Timings Title Speaker Affiliation
  9A: 08.00-09.00 Education Session (Meet the Professor)    
  Pitfalls in the design, analysis and interpretation of clinical trials Dr Richard Stephens Medical Research Council Clinical Trials Unit, London, UK
  9B: 08.00-09.00 Education Session (Meet the Professor)    
  Advances in staging - what is new? Prof Ramon Rami-Porta Hospital Mutua de Terrassa, Barcelona, Spain
  10: 09.00-09.30 Chairpersons Prof Ramon Rami-Porta
Prof Nick Thatcher
  Key Note:  Targeted therapies - a learning curve Dr Paul Bunn University of Colorado, Denver, USA
11: 09.00-11.00 Emerging Clinical Trials
Chairperson		   Dr Paul Bunn
09.30-09.50 Anti-angiogenetic approaches to lung cancer treatment Prof Nick Thatcher Christie Hospital, Manchester
09.50-10.10 New small molecule inhibitors Dr Rafael Rosell Catalan Institute of Oncology, Barcelona, Spain
10.10-10.30 Emerging pivotal trials on NSCLC Prof Egbert Smit Vrije Universiteit VUMC, Amsterdam, Netherlands
10.30-10.50 Epigenetic regulation of inflammation in COPD and lung cancer Prof Ian Adcock Imperial College London, UK
10.50-11.00 Panel Discussion
  11.00-11.30 Tea, Coffee & Exhibition Viewing
  12A:11.30-13.00 Chemoprevention Workshop
Chairpersons		   Dr Peter Boyle
Prof Stephen Lam
11.30-12.15 Lung cancer chemoprevention - potential pitfalls for implementation in the next decade Prof Nico van Zandwijk University of Sydney, Australia
12.15-12.30 Chemoprevention of Kava on lung tumorigenesis Dr Chengguo Xing University of Minnesota, Minneapolis, USA
12.30-13.00 Panel Discussion    
  12B:11.30-13.00 Molecular Pathology
Chairpersons		   Dr Rafael Rosell
Prof Gabriella Sozzi
11.30-11.45 Defining the REST-regulome in neuroendocrine lung cancer Dr Judy Coulson University of Liverpool, UK.
11.45-12.00 Clinical importance of cleaved uPAR forms in NSCLC Dr Charlotte Almasi Rigshospitalet, Copenhagen, Denmark.
12.00-12.15 Tie2 driven overexpression of calreticulin induces lung adenocarcinoma Dr Nasrin Mesaeli University of Manitoba, Winnipeg, Canada
12.15-12.30 Expression of Id-1b an alternative splicing isoform of Id-1 decreases lung cancer cell malignancy and is significantly reduced in lung tumours Dr Alfonso Calvo University of Navarra, Pamplona, Spain
12.30-12.45 Significance of Id family proteins in SCLC Dr Laleh Kamalian University of Liverpool, UK
12.45-13.00 Panel Discussion    
  12C:11.30-13.00 Forefront Molecular Biology Approaches to Lung Cancer
Chairpersons		   Dr Paul Bunn
Prof Ian Adcock
11.30-11.45 Lung Cancer DSA : A platform for discovery of biomarkers in lung cancer Dr Robert Holt ALMAC, Belfast, UK.
11.45-12.00 Integrative genetic and epigenetic analysis of lung tumour genomes Dr William Lockwood British Columbia Cancer Research Centre, Canada
12.00-12.15 Identification of human lung tumour initiating cells Dr Giulia Bertolini Fondazione IRCCS Istituto Nazionale Tumori, Italy
12.15-12.30 Differential expression of Micro RNAs in NSCLC Dr Sarah Runswick AstraZeneca, Cheshire, UK
12.30-12.45 E17K mutation in AKT1 gene in lung epidermoid carcinoma Dr Giuseppe Viglietto Universitario Germaneto, Italy
12.45-13.00 Ubiquitin pool alterations in lung cancer Dr Douglas Gray Ottawa Health Research Institute, Canada
  13.00-14.30 Lunch, Poster & Exhibition Viewing
  13:14.30-16.00 Astra Zeneca Sponsored Session    
14.30-15.20 Issues & challenges of undertaking lung cancer clinical trials Dr Alan Barge Astra Zeneca, Cheshire, UK
15.20-15.40 IRESSA Dr Alison Armour Astra Zeneca, Cheshire, UK
15.40-16.00 DNA repair Prof Jim Carmichael Astra Zeneca, Cheshire, UK
  16.00-16.30 Tea, Coffee & Exhibition Viewing
  14: 16.30-17.30 GWAS & Risk Assessment Models
Chairpersons		   Dr Margaret Spitz
Prof John Field		  
16.30-16.50 Contribution of genome-wide association studies to risk models for lung cancer Dr Paolo Boffetta IARC, Lyon,  France
16.50-17.10 Exploitation of the Liverpool Lung Project risk model in selecting populations for intervention Prof Stephen Duffy Wolfson Institute of Preventive medicine,  London, UK
17.10 - 17.30 Early lung cancer detection program using risk prediction model Prof Stephen Lam BC Cancer Agency, Vancouver, Canada
  15: 17.30-18.00 Key Note:  Molecular Epidemiology - risk & assessment Dr Margaret Spitz The University of Texas, USA
Saturday 12th July
                                                                                                             
  Session/Timings Title Speaker Affiliation
  16A: 08.00-09.00 Education Session (Meet the Professor)    
  Mesothelioma: clinical overview & discussion of possible future trials? Dr Martin Muers Leeds Chest Clinic, Leeds, UK
  16B: 08.00-09.00 Education Session (Meet the Professor)    
  EGFR opportunities & pitfalls in lung cancer therapy Dr Ken O'Byrne St. James’ Hospital, Dublin, Ireland
  17: 09.00-09.30 Chairperson Prof Francis Barr
  Employing molecular biology to understand & treat lung cancer in pre-clinical models Prof Terry Rabbitts St. James’ Hospital, Leeds, UK
  18: 09.30-11.00 Key Note:  Translating Basic Science into Clinical Practice
Chairpersons		   Prof Terry Rabbitts
Dr Martin Muers
09.30-09.50 Mining the protoeome for clinically useful lung cancer signatures: technology and trade-offs Prof David Carbone Vanderbilt -Ingram Cancer Center, USA
09.50-10.10 From biology to novel therapies for non small cell lung cancer Prof Michael Seckl Imperial Collage, London
10.10-10.30 Increased EGFR gene copy number by fish predicts sensitivity to EGFR-Inhibitors in NSCLC Dr Fred Hirsch University of Colorado, Denver, USA
10.30-10.50 Multi-centre validation study of lung adenocarcimoma based on gene expression Prof David Beer University of Michigan Medical School, Ann Arbor,, USA
10.50-11.00 Panel Discussion
  11.00-11.30 Tea, Coffee & Exhibition Viewing  
  19A: 11.30-13.00 Patient Advocacy
Chairpersons		   Dr Jesme Fox
Dr Jim Mulshine
11.30-11.45 Lung cancer journey – A patient’s perspective Mr Mark Horner Royal Navy, Hampshire, UK
11.45-12.05 Lung cancer – still a disadvantaged disease Dr Jim Mulshine Rush University & Medical Centre, Chicago, USA
12.05-12.25 Legal damages for preclinical commitment to lung cancer Dr Bernard Stewart University of New South Wales, Australia
12.25-12.45 The future of lung cancer research requires clinical trials Prof Michael Seckl Imperial College, London
12.45-13.00 Lung cancer and the patient advocacy community Dr Jesme Fox Roy Castle Lung Cancer Foundation, UK
  19B: 11.30-13.00 Translating Basic Science into Clinical Practice
Chairpersons		   Prof David Carbone
Prof David Beer
11.30-11.45 Detecting circulating tumour cells in lung cancer patients using genomic specific probes Dr Ruth Katz UT MD Anderson Cancer Center, USA
11.45-12.00 Peripheral blood SCG3 mRNA: a prognostic biomarker in SCLC Dr Adrian Moss University of Liverpool, UK
12.00-12.15 MCL-1/A1 Axis Addiction in Cisplatin Resistant NCSLC underlies sensitivity to the NOXA Mimetic Obatoclax Dr Dean Fennell Queen's University Belfast, UK
12.15-12.30 Early detection of lung cancer; is it possible a close link between CT scan screening and molecular biomarkers in body fluids? Dr Francesca Carozzi Institute of Tuscany Region, Florence, Italy
12.30-12.45 NOXA-MCL-1-BAK Axis mediates Apoptosis following 20S proteasome inhibition by Bortezomib in mesothelioma: implications for therapy Dr Dean Fennell Queen's University Belfast, UK
12.45-13.00 Inhibition of non-neuronal alpha7 nicotinic receptor as anticancer treatment for NSCLC Dr Patrizia Russo National Cancer Research Institute, Genoa, Italy
  19C - 11.30-13.00 New Agents for Lung Cancer Therapeutics
Chairpersons		   Dr Paul Bunn
Prof Michael Seckl
11.30-11.50 Profiling selective kinase inhibitors in a lung cell line panel Dr Christine Chresta AstraZeneca, Cheshire, UK
11.50-12.04 Clinical development of MAGE-A3 cancer immunotherapeutic in NSCLC: from proof of concept to phase III trials Dr Paul Taylor Wythenshawe Hospital, Manchester, UK
12.04-12.18 Low dose gem in long infusion and cisplatin for mesothelioma Dr Matjaz Zwitter Institute of Oncology, Ljubljana, Slovenia
12.18-12.32 Arsenic trioxide is highly cytotoxic to SCLC cells Dr Helen Pettersson University of Giessen, Germany
12.32-12.46 Quantification of neo-angiogenesis by micro-computed tomography in xenograft mouse model of lung cancer Dr Rajkumar Savai University of Giessen, Germany
12.46-13.00 A pilot, randomised controlled trial of Feiji recipe on quality of life of NSCLC patients Dr Zhming Shi University Hospital Shanghai,
  13.00-14.00 Lunch, Poster & Exhibition Viewing
  20A: 14.00-15.30 New Diagnostic/Prognostic Technologies
Chairpersons		   Prof Luis Montuenga
Dr Ken O’Byrne
14.00-14.15 EGFR and KRAS mutations on fine needle aspirates of lung nodules Dr A Fassina University of Padua, Padova, Italy
14.15-14.30 Analytical evaluation of the ARCHITECT® ProGRP assay Dr Toru Yoshimura Abbott, Japan
14.30-14.45 MonoTotal vs other cytokeratin markers in NSCLC Dr Jarmil Safranek Charles University and Faculty Hospital, Pilsen, Czech Republic
14.45-15.00 Genome-wide analysis of lung cancer cell lines by 500K SNP arrays Dr A Orta Center for Applied Medical Research Pamplona, Spain
15.00-15.15 NSCLC gene expression study in Estonia Dr Kristjan Valk Tartu University, Estonia
15.15-15.30 Clinical evaluation of the ARCHITECT® ProGRP assay Dr Rafael Molina IDIBAPS Hospital Clinic, Barcelona, Spain
  20B: 14.00-15.30 Interventions to facilitate smoking cessation
Chairpersons		   Mrs Chris Owens
Dr Mick Peake
 
14.00-14.15 Smoking in movies and youth tobacco use prevention Dr Stacey Anderson University of Nottingham, UK
14.15-14.30 Epidemiology of smoking among 15 to 64 year old Iranians Dr Samrad Mehrabi Shiraz University of Medical Sciences, Iran
14.30-14,45 Making support to quit smoking more accessible. Mrs Chris Owens Roy Castle Lung Cancer Foundation, Liverpool, UK
14.45-15.30 Panel Discussion - What are the government’s priorities for future tobacco control? Mrs Chris Owens Roy Castle Lung Cancer Foundation, Liverpool, UK
   
  20C: 14.00-15.30 Prognostic Biomarkers
Chairpersons		   Dr Fred Hirsch
Prof Pamela Rabbitts
14.00-14.15 Splicing factors hnRNP A1 and SF2/ASF in lung cancer cells; role in proliferation, apoptosis and invasiveness Teresa Ezponda Centre for Applied Medical Research, Pamplona, Spain
14.15-14.30 Infiltration of tumour islets by M1 macrophages is associated with extended survival in NSCLC Dr Chandra Ohri University of Leicester, UK
14.30-14.45 Expression of elF4E in NSCLC in response to IGF-1 an in vitro study Dr Farhad Mashayekhi University of Guilan, Rasht,Iran
14.45-15.00 elF4E expression and 4EBP1 phosphorylation status in lung cancer Dr Zivar Salehi University of Guilan, Rasht, Iran
15.00-15.15 Expression of livin and survivin in lung cancer Dr A Fassina University of Padua, Padova, Italy
15.15-15.30 Are CYFRA21-1 and CEA prognostic factors in female stage 1 NSCLC patients? Dr Florian Blankenburg Klinikum der Universität München –Großhadern, Germany
“Translating Basic Science into Clinical Practice”
Arena and Convention Centre Liverpool

Organising Committee:
Chair - Professor John K Field - University of Liverpool
Professor Elizabeth Brambilla – University of Grenoble, France
Dr Paul Bunn – University of Colorado, USA
Professor Stephen Duffy – Wolfson Institute - London
Professor Tim Eisen – Cambridge Research Institute
Professor Claudia Henschke – NY Presbyterian Hospital- Weill, USA
Dr Jim Mulshine – Rush University Medical Centre – USA
Professor Michael Seckl – Imperial College - London
Dr Robert A Smith – American Cancer Society, USA
Professor Gabriella Sozzi – Istituto Maxionale – Milan, Italy
Dr Margaret Spitz – MD Anderson Cancer Center - USA

Supported and Accredited:
The Faculty
Dr Deni Aberle National Cancer Institute, Bethesda, USA
Mrs Carolyn Aldige Prevent Cancer Foundation, USA
Professor David Beer University of Michigan, USA
Dr Paolo Boffetta IARC, France
Dr Peter Boyle IARC, France
Professor Christian Brambilla Unite de Pneumologie – Grenoble, France
Professor Elisabeth Brambilla University of Grenoble, France
Dr Paul Bunn University of Colorado, USA
Professor David Carbone Vanderbilt-Ingram Cancer Center, USA
Dr Tim Crook Institute of Cancer Research, UK
Professor Stephen Duffy Wolfson Institute, London
Professor Tim Eisen Cambridge Research Institute
Professor John K Field University of Liverpool, UK
Dr Jesme Fox Roy Castle Lung Cancer Foundation, UK
Professor Adi Gazdar University of Texas, USA
Professor Claudia Henschke New York Presbyterian Hospital-Weill, USA
Dr Fred Hirsch University of Colorado, USA
Professor Stephen Lam BC Cancer Agency, Vancouver, Canada
Dr Triantafillos Liloglou University of Liverpool, UK
Professor Luis Montuenga University of Navarra, Spain
Dr Jim Mulshine Rush University Medical Centre, USA
Professor Pamela Rabbitts Leeds Institute of Moledular Medicine
Professor Terry Rabbitts Leeds Institute of Molecular Medicine
Professor Mike Richards St Thomas Hospital, London
Dr Rafael Rosell Catalan Institute of Oncology, Barcelona, Spain
Professor Michael Seckl Imperial College – London
Prof Egbert Smit Vrije Universiteit, Netherlands
Dr Robert Smith American Cancer Society, USA
Professor Gabriella Sozzi Istitute Maxionale – Milan, Italy
Dr Margaret Spitz MD Anderson Cancer Center, Texas, USA
Professor Nick Thatcher Christie Hospital, UK
Dr Rob van Klaveren University Hospital, Rotterdam, Netherlands
Dr Nico van Zandwijk Netherlands Cancer Institute, Netherlands